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Background: A possible role of oxidative stress in the pathogenesis of multiple sclerosis (MS) and in experimental
autoimmune encephalomyelitis has been suggested. The detoxification enzyme NAD(P)H dehydrogenase, quinone
1 (NQO1) has been found up-regulated in MS lesions. A previous report described an association between the SNP
rs1800566 in the NQO1 gene and the risk for MS in the Greek population. The aim of this study was to replicate a
possible influence of the. SNP rs1800566 in the NQO1 gene in the risk for MS in the Spanish Caucasian population.
Methods: We analyzed allelic and genotypic frequency of NQO1 rs1800566 in 290 patients with MS and 310
healthy controls, using TaqMan Assays.
Results: NQO1 rs1800566 allelic and genotypic frequencies did not differ significantly between MS patients and
controls, and were unrelated with age of onset of MS, gender, and clinical type of MS.
Conclusions: Our results indicate that NQO1 rs1800566 does not have an effect on MS disease risk.
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Multiple sclerosis (MS) is a chronic inflammatory de-
myelinating disorder with axonal degeneration of the
central nervous system. Although the etiology of MS is
not well understood, the interplay of both genetic and
environmental factors is the most likely hypothesis [1-5].
With regard to the role of genetic factors, genome-wide
association studies (GWAS) have confirmed more than
100 loci with genome-wide significance [6-8]. According
to the most recent GWAS, approximately 22% of signals
overlapped at least one other autoimmune disease signal
[8], However, all loci except HLA showed modest odds-
ratio (OR) in the range of 1.1-1.3 [9]. In particular the
association between MS and the HLA-DRB1*15:01
haplotype has been shown to be strong.
A number or reports have suggested a possible role of
oxidative stress and lipid peroxidation in the inflammatory* Correspondence: fjavier.jimenez@salud.madrid.org
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unless otherwise stated.processes and in the pathogenesis of MS [10-40]. Reactive
oxygen species (ROS) generated in excess primarily by
macrophages and microglia, have been implicated as me-
diators of demyelination and axonal damage [10]. The
main results of studies on oxidative stress markers in the
brain, spinal cord, and CSF, both in MS patients and in
experimental autoimmune encephalomyelitis (EAE) are
summarized in a table included as an Additional file 1:
Table S1.
NAD(P)H dehydrogenase, quinone 1 (NQO1) is a phase
II detoxification enzyme that catalyzes the one-electron
reduction of endogenous and exogenous quinones, pre-
venting their participation in redox cycling and subse-
quent generation of reactive oxygen species. This enzyme
is encoded by the NQO1 gene (chromosome 16q22.1, Gene
Identity 1728) (link http://www.ncbi.nlm.nih.gov/gene/1728).
The enzymatic activity of NQO1 depends fundamentally
on a single nucleotide polymorphism (SNP) at the NQO1
locus, rs1800566 (C609T), which produces a proline-to-
serine substitution at amino acid 187 (P187S) (link http://www.
ncbi.nih.gov/pubmed/9000600). Individuals with rs1800566TT
genotype completely lack NQO1 activity, whereas thoseal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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fold decreased enzyme activity [41].
Although NQO1 polymorphisms are not mentioned
among the possible susceptibility genes in GWAS studies,
the possible role of oxidative stress in the pathogenesis of
MS makes it reasonable to analyse the possible relation-
ship between NQO1 gene polymorphisms and the risk
of MS. Moreover, NQO1 has been found to be mark-
edly up-regulated in active demyelinating MS lesions
[13,14] Stavropoulou et al. [42], in a case–control associ-
ation study involving 231 MS patients and 380 controls,
reported an association between the rs1800566CT and TT
genotypes and the risk of developing MS, and a higher in-
cidence of rs1800566CT genotype in patients with primary
progressive MS. The aim of the present study was to repli-




We studied 290 unrelated Caucasian Spanish patients
who fulfilled McDonald’s criteria for definite MS [43], with
no other previous neurological diseases. MS patients were re-
cruited from the “Multiple Sclerosis Association of Madrid”
(n = 165 cases), the Health Areas of the La-Mancha-Centro
Hospital (Alcázar de San Juan, Ciudad Real, n = 65 cases),
and University Hospitals “Doce de Octubre” (Madrid,
n = 30 cases), and “Príncipe de Asturias” (Alcalá de Henares,
Madrid, n = 30 cases). Most of these patients had partici-
pated in previous studies of genetic association with MS
risk [44-48]. The control group was composed of 310
healthy unrelated Caucasian Spanish individuals (students
or professors from the University of Extremadura) gender
and age-matched with the patients. Ethnicity and geo-
graphical origin for cases and controls was self-reported.
All the participants were included in the study after
giving written informed consent. Table 1 summarizes
the characteristics of the individuals included in the
study. The protocol was approved by the Ethics Commit-
tees of the University Hospitals “Príncipe de Asturias” and
“Infanta Cristina” (Badajoz). The study was conducted ac-
cording to the principles expressed in the declaration
of Helsinki.Table 1 Characteristics of the individuals included in the stud
Overall
Gender (females/males) 200/90
Age (mean ± SD) 43.8 ± 1
Age at onset (mean ± SD) 32.6 ± 1
Disease duration (mean ± SD) 11.2 ± 7
Expanded disability status scale (EDSS) (median, Interquartile range) 3.0, 4.50
Progression index (EDSS/MS duration) 0.5 ± 0.4
RRMS Relapsing remitting Multiple Sclerosis. SPMS Secondary Progressive Multiple SGenotyping of rs1800566 polymorphism
Genotyping for rs1800566 was performed in genomic
DNA obtained from venous blood samples of partici-
pants using TaqMan Assays (C___2091255_30, Life
Technologies, Alcobendas, Madrid, Spain). Detection
was carried out by qPCR in an Eppendorf realplex ther-
mocycler. The amplification conditions were as follows:
after a denaturation time of 10 min at 96°C, 45 cycles of
92°C 15 sec 60°C 90 sec were carried out and fluores-
cence was measured at the end of each cycle and at end-
point. All samples were determined in triplicate and
genotypes were assigned both by gene identification soft-
ware (RealPlex 2.0, Eppendorf, Madrid, Spain) and by
analysis of the reference cycle number for each fluores-
cence curve, calculated by the use of the CalQPlex algo-
rithm (Eppendorf, Madrid, Spain).
Statistical analysis
Hardy-Weinberg equilibrium (HWE) both in MS patient
and control groups was analyzed by the DeFinetti software
(http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). Allele and genotype
frequency analysis was performed with SPSS ver. 17.
For categorical variables the intergroup comparison
values were calculated using the chi-square or Fisher’s
exact tests when appropriate. For continuous variables,
the Kolmogorov-Smirnoff test was used to analyze nor-
mality in the distribution. Then, the Student two sample
t test was used for variables that followed a normal dis-
tribution (age and age at onset); the Mann–Whitney test
was used for the duration of disease and the severity
scores expanded disability status scale and progression
index, because no normal distribution was observed for
this parameter. The association between the genotypes
and the risk of developing MS was assessed by two-way
contingency table analysis (http://statpages.org/ctab2x2.
html). Statistical power was calculated for the sample size
of this study (this was determined from allele frequencies
with a genetic model analyzing the frequency for carriers
of the disease gene with Odds ratio (OR) = 1.5, p = 0.05
[49]). Two-tailed and one-tailed associations of the risk
with the variant allele for ORs of 1.5; 1.4; 1.3; 1.2; and 1.1;
were, respectively: 84.6% and 90.9%; 68.9% and 79.0%;
47.4% and 59.8%; 25.6% and 36.6%; and 9.9% and 16.56%.y
MS patients RRMS SPMS PPMS Control individuals
111/44 59/33 30/13 213/97
1.3 40.0 ± 10.5 47.2 ± 9.9 54.4 ± 10.2 43.7 ± 12.2
0.6 29.5 ± 8.5 34.9 ± 11.8 43.4 ± 11.6 –
.9 10.5 ± 8.2 12.3 ± 9.3 11.0 ± 7.7 –
2.5, 2.00 6.5, 0.90 7.5, 0.50 –
0.3 ± 0.2 0.6 ± 0.5 0.7 ± 0.4 –
clerosis. PPMS Primary Progressive Multiple Sclerosis.
Table 2 NQO1 rs1800566 genotype and allelic variants of patients with multiple sclerosis (MS) and healthy volunteers
MS PATIENTS





OR (%, 95% C.I.) P
MS WOMEN










(N (%, 95% C.I.)
Intergroup
comparison values
OR (95% CI) P
rs1800566
GENOTYPE C/C
178 (61.4, 55.8-67.0) 195 (62.9, 57.5-68.3) Reference 120 (60.0, 53.2-66.8) 134 (62.9, 56.4-69.4) Reference 58 (64.4, 54.6-74.3) 61 (62.9, 53.3-72.5) Reference
C/T 99 (34.1, 28.7-39.6) 104 (33.5, 28.3-38.8) 1.43 (0.74-1.47), 0.810 72 (36.0, 29.3-42.7) 72 (33.8, 27.5-40.2) 1.12 (0.74-1.68), 0.597 27 (30.0, 20.5-39.5) 32 (33.0, 23.6-42.3) 0.88 (0.48-1.66), 0.708
T/T 13 (4.5, 2.1-6.9) 11 (3.5, 1.5-5.6) 1.30 (0.57-2.96), 0.540 8 (4.0, 1.3-6.7) 7 (3.3, 0.9-5.7) 1.28 (0.45-3.63), 0.646 5 (5.6, 0.8-10.3) 4 (4.1, 0.2-8.1) 1.32 (0.34-5.14), 0.693
Total 290 310 200 213 90 97
Allele C 455 (78.4, 75.1-81.8) 494 (79.7, 76.5-82.8) Reference 312 (78.0, 73.9-82.1) 340 (79.8, 76.0-83.6) Reference 143 (79.4, 73.5-85.3) 154 (79.4, 73.7-85.1) Reference
Allele T 125 (21.6, 18.2-24.9) 126 (20.3, 17.2-23.5) 1.08 (0.82-1.42), 0.601 88 (22.0, 17.9-26.1) 86 (20.2, 16.4-24.0) 1.12 (0.80-1.56), 0.523 37 (20.6, 14.7-26.5) 40 (20.6, 14.9-26.3) 1.00 (0.60-1.65), 0.988
Total alleles 580 620 400 426 180 194



















Table 3 NQO1 rs1800566 genotype and allelic variants in patients with multiple sclerosis (MS), and relation with the clinical evolutive type of MS
BOUT ONSET MS (RELAPSING REMITTING
PLUS SECONDARY PROGRESSIVE MS) N
Intergroup comparison
values OR (95% CI), P
PRIMARY PROGRESSIVE
MS N (%, 95% C.I.)
Intergroup comparison
values OR (95% CI), P
CONTROLS N
(%, 95% C.I.)
rs1800566 GENOTYPE C/C 153 (61.9; 55.9-68.0) Reference 25 (58.1, 43.4-72.9) Reference 195 (62.9, 57.5-68.3)
C/T 85 (34.4; 28.5-40.3) 1.04 (0.72-1.51); 0.822 14 (32.6, 18.6-46.6) 1.05 (0.52-2.11), 0.891 104 (33.5, 28.3-38.8)
T/T 9 (3.6; 1.3-6.0) 1.04 (0.39-2.79); 0.928 4 (9.3, 0.6-18.0) 2.84 (0.84-9.59), 0.081 11 (3.5, 1.5-5.6)
Total 247 43 310
Allele C 391 (79.1; 75.6-82.7) Reference 64 (74.4, 65.2-83.6) Reference 494 (79.7, 76.5-82.8)
Allele T 103 (20.9; 17.3-24.4) 1.03 (0.76-1.40); 0.829 22 (25.6, 16.4-34.8) 1.35 (0.80-2.27), 0.262 126 (20.3, 17.2-23.5)
Total alleles 494 86 620
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The frequencies of NQO1 rs1800566 genotypes and al-
lelic variants in patients diagnosed with MS did not dif-
fer from those of controls (Table 2). The genotype and
allele frequencies in MS patients and healthy subjects
were in Hardy-Weinberg’s equilibrium. Mean age at on-
set of MS did not differ significantly between patients carry-
ing NQO1 rs1800566 C/C (mean ± SD= 32.1 ± 10.2 years,
reference), C/T (mean ± SD= 33.5 ± 11.6 years, p = 0.220)
and T/T (mean ± SD= 32.4 ± 12.0 years, p = 0.270). Associ-
ation between the rs1800566 variant and MS risk was not
observed when analyzing gender separately (Table 2). The
distribution of the NQO1 rs1800566 genotype and allelic
frequencies did not differ between each MS clinical evolu-
tive type and controls (Table 3) or in the severity scores:
Expanded Disability Status Score or EDSS (p = 0.508
and p = 0.370 for heterozygous and homozygous carriers
of the minor allele, respectively, as compared with homo-
zygous carriers of the major allele) or progression index
(p = 0.872 and p = 0.673 for heterozygous and homozy-
gous carriers of the minor allele, respectively, as compared
with homozygous carriers of the major allele).
Discussion
In contrast with the findings in the study by Stavropou-
lou et al. [42], we did not find significant differences ei-
ther in the frequencies of rs1800566 genotypes, or in the
frequencies of the allelic variants of this polymorphism
in patients with MS when compared with healthy con-
trols. In addition, rs1800566 polymorphism was neither
associated with age at onset of MS, nor with clinical type
of MS. Patient sample size and statistical power are
higher in our study than in the study by Stavropoulou
et al. [42].
A possible reason for the discrepancies between the
study by Stavropoulou et al. [42] and the present one is
the fact that the genotype distribution in the control
group of the Stavropoulou et al. [42] study was in
Hardy-Weinberg’s disequilibrium (Pearson’s p = 0.0086).
The Hardy-Weinberg’s disequilibrium was attributable
to the female control group of the study by Stavropoulou
et al. [42]. Another putative difference is that in the
study by Stavropoulou et al. [42] the genotyping analysis
was carried out by using qPCR melting curves, whereas
in our study TaqMan genotyping was used.
Several SNPs have been described within the NQO1
gene. It should be noted that most association studies
on NQO1 focusing on the SNP analyzed in this study
show a relatively high minor allele frequency (about 20%
for Caucasian populations according to 1000 genomes).
The rs1800566 analyzed in this study is common in Cau-
casian individuals; in fact it occurs in all human popula-
tions, and is classified as a pathogenic allele related with
altered susceptibility to benzene toxicity and response tochemotherapy (see http://browser.1000genomes.org/Homo_-
sapiens/Variation/Phenotype?db=core;r=16:69744645–
69745645;v=rs1800566;vdb=variation;vf=1366399).
The present study has some limitations. First, the size
of the analyzed cohorts may not be sufficient for strict
conclusions about the role of NQO1in MS (though ad-
equate to detect an OR as small as 1.5, a more modest
association would not be detected). Secondly, because
the cohort study included MS patients with different de-
grees of severity, it is not adequate for the investigation
of the influence of NQO1 genotypes on disability or se-
verity of MS. The ideal study for this purpose should be
prospective, including the genotyping of patients with a
recent diagnosis of MS and a re-examination of the same
patient cohort after similar long-term follow-up periods to
establish evolutive type).
Conclusions
Taking in account the limitations of the present study, the
results suggest that, in contrast with the Stavropoulou
et al. [42] report, NQO1 rs1800566 genotypes and allelic
variants are not associated with the risk for MS in Cauca-
sian Spanish people. The fact that this particular SNP
showed lack of association with MS risk in the present
study does not exclude the possibility that other SNPs in
the NQO1 gene could be associated with a modification in
the risk of this disease.
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